Goldenwell Biotech Reports No Revenue and Increased Net Loss in Q1 2026

Goldenwell Biotech, Inc. reported its financial results for the first quarter of 2026, revealing a continued lack of revenue generation. The company recorded no sales or service revenue for the three months ended March 31, 2026, consistent with the same period in the previous year. Operating expenses decreased to $31,335 from $36,436 year-over-year, contributing to a reduced net loss of $17,606 compared to a net loss of $38,536 in the first quarter of 2025. The company’s total assets as of March 31, 2026, were $18,754, a significant decline from $36,120 at the end of 2025, primarily due to a decrease in cash and inventory.

The company’s financial position reflects ongoing challenges, with total liabilities increasing slightly to $380,073 from $379,833 at the end of 2025. Stockholders’ equity remained negative at $(361,319), worsening from $(343,713) in the previous quarter. The company has accumulated a net loss of $1,673,722 since its inception, raising concerns about its ability to continue as a going concern. Goldenwell Biotech has indicated that its future operations depend heavily on securing additional capital to fund its business plan, which includes the construction of manufacturing facilities and workforce training.

In terms of operational developments, Goldenwell Biotech has not reported any significant changes in customer counts or product adoption rates, as it has yet to launch any products or generate sales. The company’s cash balance at the end of the quarter was $13,414, down from $26,775 at the end of 2025, indicating a need for immediate funding to cover operational expenses. The company has also noted that it has not generated positive cash flows from operating activities, with net cash used in operations amounting to $(13,364) for the quarter.

Looking ahead, Goldenwell Biotech plans to raise approximately $5 million to complete its operational setup, which includes locating a manufacturing site and training staff. The company has not arranged any financing and cannot guarantee that it will be able to raise the necessary funds through equity offerings. Management has expressed that without successful financing, the company may not be able to continue its operations or expand its business. The outlook remains uncertain as the company navigates these financial and operational challenges.